The announcement of new Pharmacy First independent prescribing pathways marks a landmark opportunity for community pharmacy. It not only brings the sector closer to making full use of pharmacists’ clinical skills but also gives patients another route to access timely care. But this is only the first step, the real test will be whether independent prescribing can be scaled up nationally, consistently and sustainably.
The opportunity is significant – for patients, prescribing pharmacists can provide a more complete service in one visit, reducing delays and avoiding unnecessary referrals elsewhere in the NHS. For pharmacy businesses, the pathways offer a chance to expand their clinical role and further strengthen their contribution to primary care.
The clinical pathways chosen will be important to the success of the service. Pharmacies must offer something that patients demand and be clear to the public and the wider NHS to understand what is (and isn’t) available. If designed well, they can demonstrate how community pharmacy can safely manage more clinical care while releasing capacity in general practice and other parts of the health service.
However, availability of access for patients must not become a postcode lottery. If Integrated Care Boards (ICBs) adopt different approval, assurance or governance processes, pharmacy businesses operating across several areas will face a patchwork quilt of differing requirements for delivery.
Capacity constraints within ICBs could also slow progress. A nationally consistent commissioning framework, with proportionate assurance and clear responsibilities, would give contractors confidence and help the service expand at pace.
Funding will be equally important. Independent prescribing brings costs beyond the consultation itself, including professional indemnity, enhanced governance, prescribing systems, IT, staffing and backfill. It is likely that some contractors provide local services because they believe strongly in the direction of travel for pharmacy, yet still expect to make a loss. That is not sustainable. The overall commissioning framework must support a safe, consistent patient offer across locations and over the long term.
Participation and public expectations must also be carefully managed. If only a relatively small number of pharmacies can initially offer the pathways, national promotion could leave patients frustrated and confused when the service is not available to them locally. The current Pharmacy First service is still not fully understood by everyone. Communications need to be clear about where the new service is available, while setting out a credible plan to increase the number of participating pharmacies.
That plan must also address the workforce needs as well as the operating model. More pharmacists need access to training, supervision and the practical experience that is essential for prescribing with confidence. Employers need the capacity to release people for professional development without affecting day-to-day services. The wider NHS must also be engaged so that general practice, urgent care and other providers fully understand the pathways, and know when to direct patients to pharmacy and trust the clinical service being offered.
Community pharmacy is ready to play a bigger part in delivering clinical care, and these pathways are an important signal of intent. Now we need a clear route from a promising start to a genuinely national offer: consistent implementation frameworks, sustainable funding, a growing prescribing workforce, wider NHS engagement and clear public awareness. If those foundations are implemented, independent prescribing can improve access for patients, create new opportunities for pharmacy teams and release valuable capacity across the NHS.
